Hypercoagulable States and New Anticoagulants, An Issue of Hematology/Oncology Clinics of North America, 1st Edition
Author :
By Mark Crowther, MD, MSc, FRCPC and Marco Donadini, MD
This issue addresses hypercoagulable states, such as antiphospholipid antibody syndrome, cancer-associated thrombosis, and coagulopathy associated with sepsis. New anticoagulants discussed include oral Xa inhibitors, oral IIa inhibitors, agents for
...view more
This issue addresses hypercoagulable states, such as antiphospholipid antibody syndrome, cancer-associated thrombosis, and coagulopathy associated with sepsis. New anticoagulants discussed include oral Xa inhibitors, oral IIa inhibitors, agents for the treatment of HIT, and use of low molecular weight heparin to improve survival in cancer patients.
This issue addresses hypercoagulable states, such as antiphospholipid antibody syndrome, cancer-associated thrombosis, and coagulopathy associated with sepsis. New anticoagulants discussed include oral Xa inhibitors, oral IIa inhibitors, agents for the treatment of HIT, and use of low molecular weight heparin to improve survival in cancer patients.
Author Information
By Mark Crowther, MD, MSc, FRCPC and Marco Donadini, MD
https://www.asia.elsevierhealth.com/hypercoagulable-states-and-new-anticoagulants-an-issue-of-hematologyoncology-clinics-of-north-america-9781437725292.html306939Hypercoagulable States and New Anticoagulants, An Issue of Hematology/Oncology Clinics of North Americahttps://www.asia.elsevierhealth.com/media/catalog/product/9/7/9781437725292_8.jpg74.2498.99USDInStock/Medicine/Hematology/Clinics/Clinics/Medicine/Hematology/Japan Titles5054622505466652550415259911526316014886536505455351451205259833This issue addresses hypercoagulable states, such as antiphospholipid antibody syndrome, cancer-associated thrombosis, and coagulopathy associated with sepsis. New anticoagulants discussed include oral Xa inhibitors, oral IIa inhibitors, agents for the treatment of HIT, and use of low molecular weight heparin to improve survival in cancer patients. This issue addresses hypercoagulable states, such as antiphospholipid antibody syndrome, cancer-associated thrombosis, and coagulopathy associated with sepsis. New anticoagulants discussed include oral Xa inhibitors, oral IIa inhibitors, agents for the treatment of HIT, and use of low molecular weight heparin to improve survival in cancer patients.00add-to-cart97814377252922011 and earlierProfessionalBy Mark Crowther, MD, MSc, FRCPC and Marco Donadini, MD20101Book152w x 229h (6.00" x 9.00")Saunders0Aug 24, 2010IN STOCKBy <STRONG>Mark Crowther</STRONG>, MD, MSc, FRCPC and <STRONG>Marco Donadini</STRONG>, MDClinicsClinicsThe Clinics: Internal MedicineUnited StatesNoNoNoNoPlease SelectPlease SelectPlease Select
